Acadia Pharmaceuticals Inc (ACAD) Institutional Ownership

Ownership Summary

Acadia Pharmaceuticals Inc (NASDAQ:ACAD) has 325 institutional investors that have filed 13F reports for the period ending December 2025.

• They owned 97.1% of outstanding stock in December 2025, down from 99.0% the prior quarter.
• They increased total shares held in Acadia Pharmaceuticals by 0.41% from last quarter, and the number of investors in ACAD increased 10.92% annually.
• Activity in ACAD broke down as 169 buyers, 114 sellers, and 42 unchanged among 325 total holders.
• In total, institutional investors held 165.7Mn shares in Acadia Pharmaceuticals as of December 2025, up by 680.29K shares quarter on quarter, and down 6.57Mn shares year over year.
• As of December 31, 2025, BAKER BROS. ADVISORS LP held the largest stake in Acadia Pharmaceuticals with 42.9Mn shares, accounting for 25.14% of total shares outstanding.
• Top purchasers of ACAD stock for the quarter ending December 2025 included VANGUARD PORTFOLIO MANAGEMENT LLC (8.67Mn), VANGUARD CAPITAL MANAGEMENT LLC (5.66Mn), Artisan Partners Limited Partnership (1.33Mn), FIRST TRUST ADVISORS LP (1.07Mn), VANGUARD FIDUCIARY TRUST CO (875.72K).
• The largest sales of ACAD for the quarter ending December 2025 came from Goldman Sachs Group Inc (1.58Mn), Rockefeller Capital Management L.P. (1.2Mn), Point72 Asset Management, L.P. (799.4K), EMERALD ADVISERS, LLC (782.56K), CITADEL ADVISORS LLC (744.7K).
• Per Business Quant, the top 10 investors in ACAD for the quarter ending December 2025 include BAKER BROS. ADVISORS LP (42.9Mn), BlackRock, Inc. (21.55Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (8.67Mn), State Street Corp (8.33Mn), RTW INVESTMENTS, LP (7.14Mn), VANGUARD CAPITAL MANAGEMENT LLC (5.66Mn), GEODE CAPITAL MANAGEMENT, LLC (3.46Mn), FIRST TRUST ADVISORS LP (3.34Mn), DIMENSIONAL FUND ADVISORS LP (3.16Mn), Palo Alto Investors LP (2.87Mn).